Quantcast
Last updated on April 17, 2014 at 21:20 EDT

Latest Fidaxomicin Stories

2013-08-01 12:26:43

NEW YORK, Aug. 1, 2013 /PRNewswire/ -- Levi & Korsinsky is investigating the Board of Directors of Optimer Pharmaceuticals, Inc. ("Optimer" or the "Company") (NasdaqGS: OPTR) for possible breaches of fiduciary duty and other violations of state law in connection with the sale of the Company to Cubist Pharmaceuticals, Inc. (Logo: http://photos.prnewswire.com/prnh/20120409/MM84375LOGO ) Click here to learn more about the investigation...

2013-08-01 08:34:41

$20.1 million in total net revenues for Q2 2013 JERSEY CITY, N.J., Aug. 1, 2013 /PRNewswire/ -- Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) announced today unaudited financial results for the second quarter ended June 30, 2013. (Logo: http://photos.prnewswire.com/prnh/20090413/LA97352LOGO) Financial Highlights Second quarter 2013 DIFICID net product sales in the U.S. and Canada of $19.0 million, compared to $15.2 million in the corresponding quarter in 2012, and up 13% from...

2013-07-25 10:08:59

Now proof of minor added benefit in severe cases or recurrences of Clostridium difficile infections In the commenting procedure on early benefit assessment pursuant to the German Act on the Reform of the Market for Medicinal Products (AMNOG), under certain circumstances drug manufacturers may submit to the Federal Joint Committee (G-BA) additional documents for dossiers. The Institute for Quality and Efficiency in Health Care (IQWiG) has now assessed such additional information for two...

2013-05-13 16:27:30

JERSEY CITY, N.J., May 13, 2013 /PRNewswire/ -- Optimer Pharmaceuticals (NASDAQ: OPTR) (the "Company" or "Optimer") today announced the appointment of Mr. Eric Sirota as Chief Operating Officer. Mr. Sirota will be responsible for directing Optimer's corporate strategy with regard to DIFICID®. "Eric has tremendous experience and has demonstrated leadership in building pharmaceutical brands in the United States and abroad and has dedicated his career to making important new...

2013-05-02 08:37:49

JERSEY CITY, N.J., May 2, 2013 /PRNewswire/ -- Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) (the "Company" or "Optimer") today announced it will report first quarter 2013 financial results after the NASDAQ Global Market closes on Thursday, May 9. The Company will host a conference call that day at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time) to discuss the financial results and highlights for the first quarter and provide a corporate update. (Logo:...

2013-04-30 08:35:44

Growing Competition Among Highly Effective Therapies Will Likely Constrain Uptake of Emerging Therapies, According to a New Report from Decision Resources BURLINGTON, Mass., April 30, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that surveyed U.S. and European infectious disease specialists agree that effect on recurrence rate is one of the drug attributes that most influences their...

2013-04-26 08:24:27

Specialised Therapeutics Australia to Launch DIFICID May 14, 2013 JERSEY CITY, N.J., April 26, 2013 /PRNewswire/ -- Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) today announced that the Therapeutic Goods Administration, the Australian regulatory body for therapeutic goods such as medicines, has approved DIFICID® (fidaxomicin) tablets for the treatment of confirmed Clostridium difficile infection (CDI) in adults. DIFICID will be available to patients in Australia starting May 14,...

2013-04-19 08:25:03

CHERTSEY, England, April 19, 2013 /PRNewswire/ -- Clostridiumdifficile infection (CDI), a potentially fatal disease, is one of the most common healthcare-associated infections[1] Urgent action is needed to improve the diagnosis and management of CDI, which is the main cause of hospital-acquired (nosocomial) diarrhoea in industrialised countries.[2] In a report launched today, during a meeting hosted by the European Healthcare and Hospital Federation (HOPE), experts...

2013-04-08 08:27:31

EXTON, Pa., April 8, 2013 /PRNewswire/ -- BioTrends Research Group and Arlington Medical Resources in their TreatmentTrends(®): Clostridium difficile Infections (EU) report find that the lack of hospital formulary inclusion, perceived high cost and reimbursement challenges, and lack of familiarity are the top three barriers to prescribing of Optimer/Cubist/Astellas' Dificlir (fidaxomicin) among surveyed physicians in the EU5. Fewer than 40 percent of represented hospitals in the EU5...

2013-03-15 08:26:38

JERSEY CITY, N.J., March 15, 2013 /PRNewswire/ -- Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) announced today that on March 14, 2013 the Compensation, Nominating, and Corporate Governance Committee of its Board of Directors approved the grant of inducement restricted stock units covering an aggregate of 5,010 shares of common stock to 4 new employees. (Logo: http://photos.prnewswire.com/prnh/20090413/LA97352LOGO) Each restricted stock unit vests over three years, with one-third...